INmune Bio Inc. Common stock (INMB) Stock Forecast — 2-Week Outlook

StockMap's current 2-week read on INmune Bio Inc. Common stock (INMB) is Neutral.

The composite score behind that read is -0.13, weighing +0.05 of bullish evidence against -0.33 bearish.

INmune Bio Inc. Common stock last closed at $1.89, +3.28% on the session.

Against the IVW growth benchmark the position is +2.48% over the forecast window.

The read is built from 15 underlying insights — 2 bullish and 13 bearish.

Agreement across those insights is 87%.

20 graded predictions for INMB so far. We publish our accuracy across thousands of stocks in the open, misses included — no per-stock hit rate is claimed on a small sample.

On the fundamentals StockMap ranks INmune Bio Inc. Common stock in the 13th percentile on return on equity, where 100 is best.

INmune Bio Inc. Common stock is classified under Health Care / Biotechnology, with a market capitalisation of $50.79M.

StockMap tracks INmune Bio Inc. Common stock as the 310th largest of the 381 companies it covers in the Biotechnology industry, part of the Health Care sector.

Across that group the current two-week reads are 301 Neutral, 63 Moderate Underperform and 17 Moderate Outperform.

On that composite INmune Bio Inc. Common stock ranks 253rd of 381 in the group, against a group median of -0.08.